Diabetic Nephropathy

Molecular therapy for Diabetic nephropathy (DN): A pharmaceutical mixture encompassing Pyridoxamine and Sildenafil (PAS) increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 19/January/2018, 10.51 pm
Molecular therapy for Diabetic nephropathy (DN): A pharmaceutical mixture encompassing Pyridoxamine and Sildenafil (PAS) increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 19/January/2018, 10.51 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA shows that “Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular…

read more

Molecular therapy for Diabetic nephropathy (DN): 14,15-Epoxyeicosatrienoic acid increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 8/December/2017, 12.18 pm
Molecular therapy for Diabetic nephropathy (DN): 14,15-Epoxyeicosatrienoic acid increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 8/December/2017, 12.18 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA shows that “Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular…

read more

Combinatorial therapy for Cardiac rejuvenation, diabetic-associated complications and Hypertension: A therapeutic mix encompassing  Aspirin and Fidarestat (AF) suppresses tumor suppressor INK4a/p16 expression, promotes cardiac repair, delays cardiac ageing and senescence, attenuates diabetic nephropathy, insulin resistance and hypertension and extends life span via up regulation of its target gene, 18/November/2017, 8.03 am
Combinatorial therapy for Cardiac rejuvenation, diabetic-associated complications and Hypertension: A therapeutic mix encompassing  Aspirin and Fidarestat (AF) suppresses tumor suppressor INK4a/p16 expression, promotes cardiac repair, delays cardiac ageing and senescence, attenuates diabetic nephropathy, insulin resistance and hypertension and extends life span via up regulation of its target gene, 18/November/2017, 8.03 am 960 720 Dr Boomi's Genom-2-Discovery Center

What we say: Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Combinatorial therapy for Cardiac rejuvenation, diabetic-associated complications and Hypertension: A therapeutic mix encompassing  Aspirin and Fidarestat (AF) suppresses tumor suppressor…

read more

Molecular therapy for Diabetic nephropathy (DN):  Epalrestat, an aldose reductase inhibitor used in the treatment of Diabetes Nephropathy, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 16/November/2017, 10.35 am
Molecular therapy for Diabetic nephropathy (DN):  Epalrestat, an aldose reductase inhibitor used in the treatment of Diabetes Nephropathy, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 16/November/2017, 10.35 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA shows that “Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular…

read more

Molecular therapy for Diabetic nephropathy (DN):  Atorvastatin (trade name: Lipitor), a lipid-lowering medication, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 15/November/2017, 5.38 am
Molecular therapy for Diabetic nephropathy (DN):  Atorvastatin (trade name: Lipitor), a lipid-lowering medication, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 15/November/2017, 5.38 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA shows that “Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular…

read more

Natural product therapy for Diabetic nephropathy (DN):  Yangonin, isolated from Kava Kava, among others, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 25/October/2017, 1.04 am
Natural product therapy for Diabetic nephropathy (DN):  Yangonin, isolated from Kava Kava, among others, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 25/October/2017, 1.04 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA shows that “Pyruvate kinase M2 activation may protect against the progression…

read more
Start Typing